Ziprasidone Outcome and Tolerability: A Practical Clinical Trial With Plasma Drug Levels

Abstract

Introduction: The aim of this study was to evaluate clinical outcomes and the tolerability of ziprasidone in relation to its plasma levels.

Methods: Thirteen inpatients affected by schizophrenia were included in the study after an acute exacerbation phase. Ziprasidone monotherapy was administered for a period of eight weeks at a mean dose of 123.07±30.38 mg/day. Plasma concentrations were measured by high-performance liquid chromatography.

Results: Nine patients completed the study. A significant clinical improvement was observed, especially in negative symptoms (P<0.05), and there was a significant improvement in extrapyramidal symptoms (P<0.01). Clinical laboratory tests, such as ECG and weight, did not significantly change from baseline. Plasma ziprasidone levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in negative symptoms.

Discussion: The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred. The findings suggest a relationship between plasma levels and the clinical response to negative symptoms of schizophrenia.

Key words

ziprasidone - second-generation antipsychotics - schizophrenia - plasma levels - serum concentrations - negative symptoms

References

• 1 Allison D-B, Casey D-E. Antipsychotic-induced weight gain: a review of the literature.  J Clin Psychiatry. 2001;  62 ((S7)) 22-31
• 2 Angermeyer M-C, Matschinger H. Attitude of family to neuroleptics.  Psychiatr Prax. 1999;  26 171-174
• 3 Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M. et al . Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.  Pharmacopsychiatry. 2004;  37 243-265
• 4 Caley C-F, Cooper C-K. Ziprasidone: the fifth atypical antipsychotic.  Ann Pharmacother. 2002;  36 839-851
• 5 Daniel D-G, Zimbroff D-L, Potkin S-G, Reeves K-R, Harrigan E-P, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.  Neuropsychopharmacology. 1999;  20 491-505
• 6 Glassman A-H, Bigger Jr J-T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.  Am J Psychiatry. 2001;  158 1774-1782
• 7 Goff D-C, Posever T, Herz L, Simmons J, Kletti N, Lapierre K. et al . An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.  J Clin Psychopharmacol. 1998;  18 296-304
• 8 Gunasekara N-S, Spencer C-M, Keating G-M. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.  CNS Drugs. 2002;  16 6456-6452
• 9 Harrigan E-P, Miceli J-J, Anziano R, Watsky E, Reeves K-R, Cutler N-R. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.  J Clin Psychopharmacol. 2004;  24 62-69
• 10 Hugenholtz G-W, Heerdink E-R, Meijer W-E, Stolker J-J, Egberts A-C, Nolen W-A. Reasons for switching between antipsychotics in daily clinical practice.  Pharmacopsychiatry. 2005;  38 122-124
• 11 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
• 12 Kay S-R, Fiszbein A, Opler L-A. The positive and negative syndrome scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 261-276
• 13 Leuner K, Muller W-E. The complexity of the dopaminergic synapses and their modulation by antipsychotics.  Pharmacopsychiatry. 2006;  39 15-20
• 14 Mamo D, Kapur S, Shammi C-M, Papatheodorou G, Mann S, Therrien F. et al . PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.  Am J Psychiatry. 2004;  161 818-825
• 15 Mauri M-C, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R. et al . Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.  Eur Psychiatry. 2001;  16 57-63
• 16 Mauri M-C, Steinhilber C-P, Marino R, Invernizzi E, Fiorentini A, Cerveri G. et al . Clinical outcome and olanzapine plasma levels in acute schizophrenia.  Eur Psychiatry. 2005;  20 55-60
• 17 Mauri M-C, Laini V, Cerveri G, Scalvini M-E, Volonteri L-S, Regispani F. et al . Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels.  Prog Neuropsychopharmacol Biol Psychiatry. 2002;  26 597-601
• 18 Pascual J-C, Madre M, Soler J, Barrachina J, Campins MJ, Alvarez E. et al . Injectable atypical antipsychotics for agitation in borderline personality disorder.  Pharmacopsychiatry. 2006;  39 117-118
• 19 Percudani M, Barbui C, Fortino I, Petrovich L. Epidemiology of first- and second-generation antipsychotics agents in Lombardy, Italy.  Pharmacopsychiatry. 2005;  38 128-131
• 20 Prior T-I, Chue P-S, Tibbo P, Baker G-B. Drug metabolism and atypical antipsychotics.  Eur Neuropsychopharmacol. 1999;  9 301-309
• 21 Simpson G-M, Angus J-W. A rating scale for extrapyramidal side effects.  Acta Psychiatr Scand Suppl. 1970;  212 11-19
• 22 Weiden P-J, Daniel D-G, Simpson G, Romano S-J. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.  J Clin Psychopharmacol. 2003;  23 595-600

Correspondence